Briakinumab for treatment of Crohn's disease: Results of a randomized trial

Inflammatory Bowel Diseases

Volumn 21, Issue 6, 2015, Pages 1329-1340

  Panaccione, Remo ^a   Sandborn, William J ^b   Gordon, Glenn L ^c   Lee, Scott D ^d   Safdi, Alan ^e   Sedghi, Shahriar ^f   Feagan, Brian G ^g   Hanauer, Stephen ^h   Reinisch, Walter ⁱ   Valentine, John F ^j   Huang, Bidan ^k   Carcereri, Roberto ^k  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Center for Digestive and Liver Diseases Inc   (Mexico)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Consultants for Clinical Research ^*  (United States)

^f Gastroenterology Associates of Central Georgia   (United States)

^g ROBARTS RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j UNIVERSITY OF UTAH   (United States)

^k ABBVIE INC   (United States)

more..

Author keywords

IL 12; IL 23; monoclonal antibody

Indexed keywords

BRIAKINUMAB; C REACTIVE PROTEIN; INTERLEUKIN 12; INTERLEUKIN 23; TUMOR NECROSIS FACTOR INHIBITOR; INTERLEUKIN 12P40; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; ARTICLE; ASTHMA; BASAL CELL CARCINOMA; CONTROLLED STUDY; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; REMISSION; RESPIRATORY DISTRESS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MIDDLE AGED; TIME FACTOR;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; MALE; MIDDLE AGED; REMISSION INDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929910457     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000366     Document Type: Article

References (22)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
2. Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int J Colorectal Dis. 1999;14:47-51.
3. Sarra M, Pallone F, Macdonald TT, et al. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010;16:1808-1813.
4. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis. 2006;12:9-15.
5. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756-1767.
6. Veldman G. Targeting the p40 cytokines interleukin (IL)-12 and IL-23 in Crohn's disease. Drug Discov Today Ther Strateg. 2006;3:375-379.
7. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203:2473-2483.
8. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182:1281-1290.
9. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
10. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
11. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
12. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
13. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
14. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008;372:67-81.
15. Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165:652-660.
16. Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165: 661-668.
17. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011;365:1586-1596.
18. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
19. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008;135: 1130-1141.
20. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519-1528.
21. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
22. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661-665.